Puma Biotechnology, Inc. (PBYI) Stock Price & Analysis
Puma Biotechnology, Inc. (PBYI) rose 1.49% to USD 9.55 as of September 8, 2026 at 05:01 UTC, according to Nexqual real-time market data.
PBYI last closed at USD 9.55; the session ranged USD 9.31–9.64 on volume of 185,911 shares. Market capitalization is —, with a 52-week range of USD 4.3–9.74 (NMS). Source: Nexqual, September 8, 2026 at 05:01 UTC.
Key Statistics (as of September 8, 2026 at 05:01 UTC)
| Price | USD 9.55 |
|---|---|
| Change | ▲ 1.49% (up) |
| Previous Close | USD 9.55 |
| Open | USD 9.55 |
| Day Range | USD 9.31 – 9.64 |
| 52-Week Range | USD 4.3 – 9.74 |
| Volume | 185,911 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (PBYI)
Nexqual's technical model rates PBYI "BUY" based on 5 bullish and 1 bearish signals across 128 daily candles, as of September 8, 2026 at 05:01 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 59.24 (neutral) |
| vs SMA50 | Above (USD 8.52) |
| MACD | 0.3 (positive) |
From Puma Biotechnology, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Partnerships
- We are currently party to several sub-licenses in various regions outside the United States, including Europe (excluding Ukraine), Australia, Canada, China, Southeast Asia, Israel, South Korea, Russia and various countries and territories in Central America, South America, Africa and the Middle East.   Alisertib   In September 2022, we entered into an exclusive license agreement with Takeda to license the worldwide research and development and commercial rights to alisertib.
- In February 2013, we reached agreement with the FDA under a Special Protocol Assessment ("SPA") for our Phase III clinical trial (PUMA-NER-1301 or the NALA trial) of neratinib in patients with HER2-positive metastatic breast cancer who have failed two or more prior treatments (third-line disease).
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AGIO | Agios Pharmaceuticals, Inc. | USD 33.1 | ▼ 3.02% |
| PTCT | PTC Therapeutics, Inc. | USD 69.3 | ▼ 3.47% |
| KPTI | Karyopharm Therapeutics Inc. | USD 1.79 | ▲ 0% |
| MGNX | MacroGenics, Inc. | USD 4.4 | ▲ 1.85% |
| RARE | Ultragenyx Pharmaceutical Inc. | USD 15.3 | ▼ 42.33% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:01 UTC. This page is informational and not investment advice.